GH:NSD-Guardant Health Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 51.52

Change

+1.45 (+2.90)%

Market Cap

USD 4.82B

Volume

0.38M

Avg Analyst Target

USD 78.46 (+52.29%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


GH Stock Forecast & Price:
Based on the Guardant Health Inc stock forecasts from 10 analysts, the average analyst target price for Guardant Health Inc is USD 78.46 over the next 12 months. Guardant Health Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Guardant Health Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Guardant Health Inc’s stock price was USD 51.52. Guardant Health Inc’s stock price has changed by +6.95% over the past week, +10.30% over the past month and -51.96% over the last year.

About Guardant Health Inc (GH:NSD)

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; an ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-25 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina Inc

-3.09 (-1.39%)

USD34.93B 50.02 -10.02
IDXX IDEXX Laboratories Inc

-5.17 (-1.24%)

USD34.13B 52.57 36.21
ICLR ICON PLC

+1.74 (+0.80%)

USD17.67B 37.71 18.05
PRAH PRA Health Sciences, Inc

N/A

USD10.70B 50.52 25.79
EXAS EXACT Sciences Corporation

-0.44 (-1.02%)

USD7.50B N/A -17.84
MEDP Medpace Holdings Inc

-1.00 (-0.46%)

USD6.90B 33.66 25.00
NTRA Natera Inc

+0.35 (+0.94%)

USD4.00B N/A -7.19
SYNH INC Research Holdings Inc

-0.10 (-0.29%)

USD3.45B 11.61 8.84
NEOG Neogen Corporation

+0.07 (+0.43%)

USD3.43B 45.37 45.80
OLK Olink Holding AB ADR

-0.05 (-0.23%)

USD2.86B N/A -100.32

ETFs Containing GH

Symbol Name Weight Mer Price(Change) Market Cap
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.68 %

-0.09 (-1.00%)

USD6.55M

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -48.49% 69% D+ 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.49% 69% D+ 33% F
Trailing 12 Months  
Capital Gain -51.81% 67% D+ 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.81% 67% D+ 33% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 13.10% 60% D- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.10% 60% D- 75% C
Risk Return Profile  
Volatility (Standard Deviation) 54.28% 44% F 23% F
Risk Adjusted Return 24.14% 67% D+ 64% D
Market Capitalization 4.82B 91% A- 91% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 29.60 4% F 3% F
Price / Cash Flow Ratio -23.05 88% B+ 76% C
EV/EBITDA -9.69 87% B+ 82% B-
Management Effectiveness  
Return on Equity -125.48% 17% F 14% F
Return on Invested Capital -21.18% 57% F 35% F
Return on Assets -15.80% 56% F 30% F
Debt to Equity Ratio 175.94% 19% F 12% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 3.46 48% F 46% F
Short Percent 5.26% 47% F 30% F
Beta 0.63 78% C+ 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector